Table 1 Results of HIV molecular testing, Antigen/Antibody screening assay, and CD4 count from time first presentation (June 2014) to initiation of ARV therapy
From: Correction to: Rapid development of HIV elite control in a patient with acute infection
Time | Viral Load (RNA copies/ml) | Forth Generation Antigen/Antibody HIV Test (s/co –relative quantity of HIV Ab) | Confirmatory Test | CD4+ T Cells/uL (%) | |||
|---|---|---|---|---|---|---|---|
Viral Load | SCA | ARCHITECT (S/Co) | VIDAS (S/Co) | GS | INNO-LIA | ||
Jun 2014 | 71550a | – | 1 b | NEG | NEG | – | – |
Oct 2014 | <  200 | – | 11.1c | 13.72 c | – | gp41 (3+), p31 (1+), p24 (3+), p17 (1+) c | – |
Nov 2014 | <  40 | – | – | – | – | – | 616 (45%) |
Dec 2014 | – | – | – | – | – | – | – |
Oct 2015 | <  40 | – | – | – | – | – | 459 (46%) |
Apr 2016 | <  40 | – | – | – | – | – | 558 (40%) |
Sep 2016 | – | 0.84d | – | – | – | – | – |
Antiretroviral therapy commenced September 2016 d | |||||||
 Oct 16 | – | – | – | – | – | – | 585 (47%) |